Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics Inc (NASDAQ: JSPR) is a clinical-stage biotechnology company pioneering safer conditioning agents for stem cell transplants and gene therapies. This dedicated news hub provides investors and medical professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships central to advancing curative treatments.
Discover comprehensive coverage of JSPR's progress in hematopoietic stem cell research, including trial results for jsp191 and related therapeutic platforms. Our curated collection features press releases on FDA interactions, collaboration announcements with research institutions, and analyses of scientific breakthroughs in antibody-based conditioning.
Key updates include progress reports on:
• Phase clinical trials evaluating novel conditioning regimens
• Strategic licensing agreements enhancing therapeutic pipelines
• Peer-reviewed research publications validating scientific approaches
• Financial disclosures supporting continued R&D efforts
Bookmark this page for direct access to Jasper Therapeutics' official communications and third-party analyses, carefully vetted for accuracy and relevance. Check regularly for developments that could influence the future of stem cell transplantation protocols and gene therapy accessibility.
Jasper Therapeutics (Nasdaq: JSPR) has announced the first patient dosing in its Phase 1b/2a ETESIAN clinical study evaluating briquilimab in allergic asthma. The study will test a single 180mg subcutaneous dose of briquilimab in approximately 30 patients across up to 7 sites in Canada. This marks Jasper's third clinical program for briquilimab in inflammatory diseases driven by mast cell activity. The double-blind, placebo-controlled challenge study aims to demonstrate proof-of-concept in asthma, with initial data expected in the second half of 2025. Key assessments will include early and late asthmatic response, airway hyperresponsiveness, and mast cell depletion and recovery.
Jasper Therapeutics (Nasdaq: JSPR), a clinical stage biotech company developing briquilimab, announces its participation in three upcoming investor conferences. The company will present at the Stifel 2024 Healthcare Conference (Nov 18-19) with a fireside chat on Nov 18 at 9:45 AM ET, the Jefferies London Healthcare Conference (Nov 19-21), and the 7th Annual Evercore ISI HealthCONx Conference (Dec 3-5) with a fireside chat on Dec 3 at 3:25 PM ET. Briquilimab is a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Jasper Therapeutics (JSPR) reported Q3 2024 financial results and provided updates on its briquilimab development programs. The company reported positive preliminary data from the SPOTLIGHT study in CIndU, with 93% of participants in the 40mg and 120mg dose cohorts achieving clinical response. Financial highlights include cash position of $92.5 million, R&D expenses of $14.5 million, and a net loss of $18.6 million ($1.24 per share). The company discontinued its LR-MDS program but advanced its chronic urticaria and asthma studies, with initial BEACON study data expected in January 2025.
Jasper Therapeutics (Nasdaq: JSPR) will present preclinical data for briquilimab, their novel antibody therapy targeting c-Kit (CD117), at the ACAAI Annual Scientific Meeting in Boston from October 24-28, 2024. The therapy aims to treat mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Three presentations will showcase promising preclinical results demonstrating briquilimab's effectiveness in mast cell depletion and its ability to bind c-Kit with high potency. The studies include both in-vitro data and non-human primate research, supporting the drug's pharmacodynamics. All presentations will take place on Friday, October 25, 2024, in Exhibit Hall A.
Jasper Therapeutics (JSPR) announced an expansion of its clinical program for chronic urticaria treatments. The company is initiating an open-label extension study that will include patients from both BEACON and SPOTLIGHT studies. Additionally, Jasper received regulatory approval in the US and EU to add a 360mg single-dose cohort to the BEACON study in chronic spontaneous urticaria (CSU), with enrollment already begun.
Initial data from all doses up to 240mg in the BEACON study will be reported during the week of January 6th, 2025, while data from the new 360mg cohort is expected in the first half of 2025. The company plans to commence registrational studies in the second half of 2025.
Jasper Therapeutics (Nasdaq: JSPR) reported positive data from its SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adults with chronic inducible urticaria (CIndU). Key findings include:
- 14 of 15 participants (93%) achieved a clinical response within 6 weeks
- In the 120mg dose cohort, 10 of 12 participants (83%) experienced a complete response
- No serious adverse events or grade 3+ adverse events reported
- Significant reductions in tryptase observed, correlating with clinical responses
The company plans to enroll a 180mg dose cohort and expects to present full data in the first half of 2025. Additionally, Jasper anticipates reporting initial data from all cohorts of the BEACON study in chronic spontaneous urticaria during the week of January 6th, 2025.
Jasper Therapeutics (Nasdaq: JSPR) announced Health Canada's clearance of its Clinical Trial Application for a Phase 1b/2a asthma challenge study evaluating briquilimab. The study, set to enroll 30 patients across Canada and the EU, aims to demonstrate proof-of-concept for mast cell depletion as an effective mechanism in asthma treatment. Key assessments include early and late asthmatic response, airway hyperresponsiveness changes, and mast cell depletion.
The company plans to begin dosing patients in Q4 2024 and report initial data in H2 2025. Additionally, Jasper received trademark approval for its proprietary Jasper c-Kit Mouse™ model, which enables direct testing of c-Kit inhibitors across various diseases, overcoming limitations of standard models.
Jasper Therapeutics (Nasdaq: JSPR), a biotech company developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell-driven diseases, has announced its participation in three upcoming investor conferences in September 2024:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept 9-11, fireside chat on Sept 10 at 3:00 p.m. ET)
2. 2024 Cantor Fitzgerald Healthcare Conference (Sept 17-19, fireside chat on Sept 17 at 2:30 p.m. ET)
3. TD Cowen Chronic Urticaria Summit (Sept 20, fireside chat at 12:00 p.m. ET)
Live webcasts of the presentations will be available on Jasper's Investor Relations website, with archived replays accessible for 30 days after the live broadcasts.
Jasper Therapeutics (Nasdaq: JSPR) reported Q2 2024 financial results and corporate updates. Key highlights include:
1. Faster-than-expected enrollment in BEACON and SPOTLIGHT studies for briquilimab in chronic urticaria.
2. Additional 180mg Q8W dosing cohort added to BEACON study.
3. Initial data from BEACON study (up to 240mg dosing) expected in Q4 2024.
4. Expanded mast cell portfolio with new asthma program.
5. Q2 2024 financials: $106.8M cash on hand, $11.3M R&D expenses, $4.7M G&A expenses, $15.0M net loss ($0.97 per share).
The company remains optimistic about briquilimab's potential in mast cell-driven diseases and plans to present initial data from both BEACON and SPOTLIGHT studies later this year.
Jasper Therapeutics (Nasdaq: JSPR), a clinical-stage biotech firm specializing in briquilimab, an antibody therapy for mast cell-driven diseases, announced the appointment of Svetlana Lucas, Ph.D., to its Board of Directors, effective June 18, 2024. Dr. Lucas brings over 20 years of experience in strategy, commercialization, and business development, notably in immunology and oncology. She has held key roles at Scribe Therapeutics, Tizona Therapeutics, and Amgen. Her appointment follows the departure of Anna French, a founding investor and Board member. Dr. Lucas expressed enthusiasm for contributing to Jasper's growth and the potential of briquilimab to address various diseases.
FAQ
What is the current stock price of Jasper Therapeutics (JSPR)?
What is the market cap of Jasper Therapeutics (JSPR)?
